Dynamic survivin in head and neck cancer: Molecular mechanism and therapeutic potential

International Journal of Cancer

Volumn 121, Issue 6, 2007, Pages 1169-1174

  Lippert, Burkhard M ^a   Knauer, Shirley K ^a   Fetz, Verena ^a   Mann, Wolf ^a   Stauber, Roland H ^a,b  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Apoptosis; Cell cycle; Chromosomal passenger complex; CPC; Crm1; Head and neck cancer; LMB; Nucleo cytoplasmic transport

Indexed keywords

EXPORTIN 1; SURVIVIN;

APOPTOSIS; CANCER RESEARCH; CARCINOGENESIS; CENTROMERE; HEAD AND NECK CANCER; HUMAN; MITOSIS; NUCLEOCYTOPLASMIC TRANSPORT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SHORT SURVEY; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; TREATMENT FAILURE;

ANIMALS; HEAD AND NECK NEOPLASMS; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 34548101130     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22941     Document Type: Short Survey

References (54)

1. Forastiere AA, Ang K, Brizel D, Brockstein BE, Dunphy F, Eisele DW, Goepfert H, Hicks WL, Jr, Kies MS, Lydiatt WM, Maghami E, McCaffrey T, et al. Head and neck cancers. J Natl Compr Canc Netw 2005;3:316-91.
2. Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer 2004;4:448-56.
3. Braakhuis BJ, Brakenhoff RH, Leemans CR. Second field tumors: a new opportunity for cancer prevention? Oncologist 2005;10:493-500.
4. Forastiere AA, Trotti A, Pfister DG, Grandis JR. Head and neck cancer: recent advances and new standards of care. J Clin Oncol 2006;24:2603-5.
5. Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A, Ozsahin EM, Jacobs JR, Jassem J, Ang KK, Lefebvre JL. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (#9501). Head Neck 2005;27:843-50.
6. Lippert BM, Dunne AA, Wemer JA. Side effects in multimodal treatment concepts in carcinomas of the head and neck. Front Radiat Ther Oncol 2002;37:185-90.
7. Kim MM, Califano JA. Molecular pathology of head-and-neck cancer. Int J Cancer 2004;112:545-53.
8. Chung CH, Parker JS, Ely K, Carter J, Yi Y, Murphy BA, Ang KK, El-Naggar AK, Zanation AM, Cmelak AJ, Levy S, Slebos RJ, et al. Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-κB signaling as characteristics of a high-risk head and neck squamous cell carcinoma. Cancer Res 2006;66:8210-18.
9. Ha PK, Califano JA. Promoter methylation and inactivation of tumour-suppressor genes in oral squamous-cell carcinoma. Lancet Oncol 2006;7:77-82.
10. Gastman BR. Apoptosis and its clinical impact. Head Neck 2001;23:409-25.
11. Okada H, Mak TW. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer 2004;4:592-603.
12. Sharma H, Sen S, Mathur M, Bahadur S, Singh N. Combined evaluation of expression of telomerase, survivin, and anti-apoptotic Bcl-2 family members in relation to loss of differentiation and apoptosis in human head and neck cancers. Head Neck 2004;26:733-40.
13. Reed JC. Apoptosis-based therapies. Nat Rev Drug Discov 2002;1:111-21.
14. Cohen EE. Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2006;24:2659-65.
15. Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 2005;5:876-85.
16. Salvesen GS, Duckett CS. IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 2002;3:401-10.
17. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003;3:46-54.
18. Engels K, Knauer SK, Metzler D, Simf C, Struschka O, Bier B, Mann W, Kovacs AF, Stauber RH. Dynamic intracellular survivin as an early prognostic marker in oral squamous cell carcinomas - underlying molecular mechanism and potential. J Pathol 2007;211:532.
19. Freier K, Pungs S, Sticht C, Flechtenmacher C, Lichter P, Joos S, Hofele C. High survivin expression is associated with favorable outcome in advanced primary oral squamous cell carcinoma after radiation therapy. Int J Cancer 2007;120:942-6.
20. Lo Muzio L, Farina A, Rubini C, Pezzetti F, Stabellini G, Laino G, Santarelli A, Pannone G, Bufo P, de Lillo A, Carinci F. Survivin as prognostic factor in squamous cell carcinoma of the oral cavity. Cancer Lett 2005;225:27-33.
21. Altieri DC. The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr Opin Cell Biol 2006;18:609-15.
22. Lens SM, Vader G, Medema RH. The case for survivin as mitotic regulator. Curr Opin Cell Biol 2006;18:616-22.
23. Li F. Role of survivin and its splice variants in tumorigenesis. Br J Cancer 2005;92:212-16.
24. Noton EA, Colnaghi R, Tate S, Starck C, Carvalho A, Ko Ferrigno P, Wheatley SP. Molecular analysis of survivin isoforms: evidence that alternatively spliced variants do not play a role in mitosis. J Biol Chem 2006;281:1286-95.
25. Knauer SK, Bier C, Schlag P, Fritzmann J, Dietmaier W, Rodel F, Klein-Hitpass L, Kovacs AF, Döring C, Hansmann M-L, Hofmann WK, Kunkel M, et al. The survivin isoform survivin-3B is cytoprotective and can function as a chromosomal passenger complex protein. Cell Cycle 2007;6:553-62.
26. Chakrabarti S, Sengupta S, Sengupta A, Basak SN, Roy A, Panda C, Roychoudhury S. Genomic instabilities in squamous cell carcinoma of head and neck from the Indian population. Mol Carcinog 2006;45:270-7.
27. Minhas KM, Singh B, Jiang WW, Sidransky D, Califano JA. Spindle assembly checkpoint defects and chromosomal instability in head and neck squamous cell carcinoma. Int J Cancer 2003;107:46-52.
28. Weaver BA, Cleveland DW. Decoding the links between mitosis, cancer, and chemotherapy: the mitotic checkpoint, adaptation, and cell death. Cancer Cell 2005;8:7-12.
29. Knauer SK, Bier C, Habtemichael N, Stauber RH. The survivin-Crm1 interaction is essential for chromosomal passenger complex localization and function. EMBO Rep 2006;7:1259-65.
30. Vagnarelli P, Earnshaw WC. Chromosomal passengers: the four-dimensional regulation of mitotic events. Chromosoma 2004;113: 211-22.
31. Altieri DC. Targeted therapy by disabling crossroad signaling networks: the survivin paradigm. Mol Cancer Ther 2006;5:478-82.
32. Li F, Yang J, Ramnath N, Javle MM, Tan D. Nuclear or cytoplasmic expression of survivin: what is the significance? Int J Cancer 2005;114:509-12.
33. Pemberton LF, Paschal BM. Mechanisms of receptor-mediated nuclear import and nuclear export. Traffic 2005;6:187-98.
34. Heger P, Lohmaier J, Schneider G, Schweimer K, Stauber RH. Qualitative highly divergent nuclear export signals can regulate export by the competition for transport cofactors in vivo. Traffic 2001;2:544-55.
35. Xu L, Massague J. Nucleocytoplasmic shuttling of signal transducers. Nat Rev Mol Cell Biol 2004;5:209-19.
36. Ferrando-May E. Nucleocytoplasmic transport in apoptosis. Cell Death Differ 2005;12:1263-76.
37. Budhu AS, Wang XW. Loading and unloading: orchestrating centrosome duplication and spindle assembly by Ran/Crm1. Cell Cycle 2005;4:1508-12.
38. Colnaghi R, Connell CM, Barrett RM, Wheatley SP. Separating the anti-apoptotic and mitotic roles of survivin. J Biol Chem 2006;281:33450-6.
39. Rodriguez JA, Lens SM, Span SW, Vader G, Medema RH, Kruyt FA, Giaccone G. Subcellular localization and nucleocytoplasmic transport of the chromosomal passenger proteins before nuclear envelope breakdown. Oncogene 2006;25:4867-79.
40. Knauer SK, Bier C, Schlag P, Fritzmann J, Dietmaier W, Rodel F, Klein-Hitpass L, Kovacs AF, Doring C, Hansmann M-L, Hofmann WK, Kunkel M, et al. The survivin isoform survivin-3B is cytoprotective and can function as a chromosomal passenger complex protein. Cell Cycle (in press) 2007.
41. Knauer SK, Kramer OH, Knosel T, Engels K, Rodel F, Kovacs AF, Dietmaier W, Klein-Hitpass L, Habtemichael N, Schweitzer A, Brieger J, Rodel C, et al. Nuclear export is essential for the tumor-promoting activity of survivin. FASEB J 2007;21:207-16.
42. Rodel F, Hoffmann J, Distel L, Herrmann M, Noisternig T, Papadopoulos T, Sauer R, Rodel C. Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 2005;65:4881-7.
43. Dasso M. Cell biology: new cog for a familiar machine. Nature 2005;435:899-900.
44. Knauer SK, Moodt S, Berg T, Liebel U, Pepperkok R, Stauber RH. Translocation biosensors to study signal-specific nucleo-cytoplasmic transport, protease activity and protein-protein interactions. Traffic 2005;6:594-606.
45. Vigneri P, Wang JY. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med 2001;7:228-34.
46. Sun C, Nettesheim D, Liu Z, Olejniczak ET. Solution structure of human survivin and its binding interface with smac/diablo. Biochemistry 2005;44:11-17.
47. Knauer SK, Stauber RH. Development of an autofluorescent translocation biosensor system to investigate protein-protein interactions in living cells. Anal Chem 2005;77:4815-20.
48. Vassilev LT. MDM2 inhibitors for cancer therapy. Trends Mol Med 2007;13:23-31.
49. Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, Nakayama T, Graham JA, Demur C, Hercend T, Diu-Hercend A, Su M, Golec JM, et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004;10:262-7.
50. Teymoortash A, Bien S, Dalchow C, Sesterhenn A, Lippert BM, Werner JA. Selective high-dose intra-arterial cisplatin as palliative treatment for incurable head and neck cancer. Onkologie 2004;27:547-51.
51. Kovacs AF. Intra-arterial induction high-dose chemotherapy with cisplatin for oral and oropharyngeal cancer: long-term results. Br J Cancer 2004;90:1323-8.
52. Marioni G, Ottaviano G, Marchese-Ragona R, Giacomelli L, Bertolin A, Zanon D, Marino F, Staffieri A. High nuclear expression of the apoptosis inhibitor protein survivin is associated with disease recurrence and poor prognosis in laryngeal basaloid squamous cell carcinoma. Acta Otolaryngol 2006;126:197-203.
53. Pizem J, Cor A, Gale N. Survivin expression is a negative prognostic marker in laryngeal squamous cell carcinoma and is associated with p53 accumulation. Histopathology 2004;45:180-6.
54. Knauer SK, Mann W, Stauber RH. Survivin's dual role: an export's view. Cell Cycle 2007;6:518-21.